Effect of Short-Term Rosiglitazone Therapy in Peritoneal Dialysis Patients

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Rosiglitazone, a thiazolidinedione (TZD), is a selective peroxisome proliferator-activated receptor-gamma (PPAR-) agonist widely used in the treatment of type 2 diabetes mellitus (1). In addition to effectively controlling glycemia by improving insulin sensitivity, TZDs have pleiotropic effects on endothelial function, lipids, blood pressure, and inflammation (2). Whether the improvements in various risk factors reduce cardiovascular morbidity and mortality is a matter of debate (3,4). Data on the effect of rosiglitazone on blood pressure, peripheral edema, blood lipids, peritoneal membrane characteristics, and oxidative stress on the peritoneal dialysis (PD) population are scarce or lacking in the current literature (5,6).
Original languageEnglish
Pages (from-to)108-111
Number of pages4
JournalPeritoneal Dialysis International
Volume29
Issue number1
Publication statusPublished - 2009

Keywords

  • Rosiglitazone
  • peritoneal dialysis
  • short-term effect

Fingerprint

Dive into the research topics of 'Effect of Short-Term Rosiglitazone Therapy in Peritoneal Dialysis Patients'. Together they form a unique fingerprint.

Cite this